Skip to main content
SpringerLink
Log in

The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma

  • Concise Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The serine protease inhibitor of Kazal-type (SPINK) 9 was reported to be exclusively expressed in palmoplantar skin. SPINK9 is a specific inhibitor of the serine protease kallikrein-related peptidase 5 (KLK5), which contributes to the desquamation process of the stratum corneum. Herein, we demonstrated that SPINK9 is also expressed in lichen simplex chronicus. Moreover, we observed expression of SPINK9 in 51 % of lesions of actinic keratosis and squamous cell carcinoma. In conclusion, we demonstrate that SPINK9 is not only expressed in healthy palmoplantar skin, but also in dermatologic disorders like lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

KLK:

Kallikrein-related peptidase

SPINK:

Serine protease inhibitor of Kazal-type

LSC:

Lichen simplex chronicus

References

  1. Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 282(6):3640–3652

    Article  CAS  PubMed  Google Scholar 

  2. Brattsand M, Stefansson K, Hubiche T, Nilsson SK, Egelrud T (2009) SPINK9: a selective, skin-specific kazal-type serine protease inhibitor. J Invest Dermatol 129(7):1656–1665

    Article  CAS  PubMed  Google Scholar 

  3. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A (2009) Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 206(5):1135–1147

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G (2004) Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 122(5):1235–1244

    Article  CAS  PubMed  Google Scholar 

  5. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafe JL, Wilkinson J, Taieb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25(2):141–142

    Article  CAS  PubMed  Google Scholar 

  6. Eissa A, Amodeo V, Smith CR, Diamandis EP (2011) Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 286(1):687–706

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Fernandez-Figueras MT, Carrato C, Saenz X, Puig L, Musulen E, Ferrandiz C, Ariza A (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29(5):991–997. doi:10.1111/jdv.12848

    Article  CAS  PubMed  Google Scholar 

  8. Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand HB, Tornell J, Wallbrandt P, Wennbo H, Egelrud T (2002) Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 118(3):444–449

    Article  CAS  PubMed  Google Scholar 

  9. Kantyka T, Fischer J, Wu Z, Declercq W, Reiss K, Schroder JM, Meyer-Hoffert U (2011) Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6. Peptides 32(6):1187–1192. doi:10.1016/j.peptides.2011.03.009

    Article  CAS  PubMed  Google Scholar 

  10. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, Takehara K, Diamandis EP (2005) Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol 153(2):274–281

    Article  CAS  PubMed  Google Scholar 

  11. Komatsu N, Takata M, Otsuki N, Toyama T, Ohka R, Takehara K, Saijoh K (2003) Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 121(3):542–549

    Article  CAS  PubMed  Google Scholar 

  12. Magert HJ, Standker L, Kreutzmann P, Zucht HD, Reinecke M, Sommerhoff CP, Fritz H, Forssmann WG (1999) LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 274(31):21499–21502

    Article  CAS  PubMed  Google Scholar 

  13. Meyer-Hoffert U, Schroder JM (2011) Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 15(1):16–23. doi:10.1038/jidsymp.2011.2

    Article  CAS  PubMed  Google Scholar 

  14. Meyer-Hoffert U, Wu Z, Kantyka T, Fischer J, Latendorf T, Hansmann B, Bartels J, He Y, Glaser R, Schroder JM (2010) Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J Biol Chem 285(42):32174–32181

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Meyer-Hoffert U, Wu Z, Schroder JM (2009) Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS One 4(2):e4372. doi:10.1371/journal.pone.0004372

    Article  PubMed Central  PubMed  Google Scholar 

  16. Simon M, Jonca N, Guerrin M, Haftek M, Bernard D, Caubet C, Egelrud T, Schmidt R, Serre G (2001) Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 276(23):20292–20299

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Sandra Harms for excellent technical assistance. This work was supported by grants of German Research Foundation Me2037/3-3. This work was part of the medical doctor thesis of Lisa Redelfs.

Author information

Authors and Affiliations

  1. Department of Dermatology, University Clinic Schleswig-Holstein, Campus Kiel, Kiel, Germany

    Lisa Redelfs, Jan Fischer, Clemens Weber, Zhihong Wu & Ulf Meyer-Hoffert

  2. Institute of Biochemistry and Cell Biology, Zhejiang University of Science and Technology, Hangzhou, 310023, China

    Zhihong Wu

Authors
  1. Lisa Redelfs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhihong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulf Meyer-Hoffert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulf Meyer-Hoffert.

Ethics declarations

Conflict of interest

The authors state no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Redelfs, L., Fischer, J., Weber, C. et al. The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma. Arch Dermatol Res 308, 133–137 (2016). https://doi.org/10.1007/s00403-015-1616-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-015-1616-5

Keywords

Search

Navigation